Companies › GRI

GRI Bio Inc (GRI)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001824293 · EDGAR filings · Updated 2026-06-18

GRI Bio Inc (GRI) has reported institutional ownership of 1.6%, with 6 institutional managers holding positions valued at $64.7K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-06-18 — Current report (8-K) filed
• 2026-05-14 — Current report (8-K) filed
• 2026-05-13 — SCHEDULE 13G/A filed
• 2026-05-13 — Quarterly report (10-Q) filed
• 2026-02-13 — SCHEDULE 13G/A filed
• 2026-02-10 — SCHEDULE 13G/A filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, GRI Bio Inc has 6 institutional holders and institutional ownership of 1.6%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

Galmed Pharmaceuticals Ltd (GLMD) · AGAPE ATP CORP (ATPC) · IMMURON LTD (IMRN) · Adial Pharmaceuticals Inc (ADIL) · BGM Group Ltd (BGM) · SILEXION THERAPEUTICS CORP (SLXN)